Skip to content

Effects of metformin, vitamin E and herbal products contain cynara scolymus for the treatment of fatty liver

The therapeutic effects of co-administration of metformin, vitamin E and plant products contain cynara scolymus in patients with fatty liver

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017040429278N1
Enrollment
90
Registered
2017-07-27
Start date
2017-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver. (Nonalcoholic steatohepatitis (NASH

Interventions

Intervention 1: Metformin, 500 mg, twice a day, for three months. Intervention 2: Vitamin E 400 IU, once daily, for three months. Intervention 3: Artichoke herbal preparation containing 320 mg three t
Treatment - Drugs
Metformin, 500 mg, twice a day, for three months
Vitamin E 400 IU, once daily, for three months
Artichoke herbal preparation containing 320 mg three times a day, for three days

Sponsors

Vice Chancellor for Research and Technology Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria included: 1- Confirmed fatty liver disease using ultrasound, 2- High liver enzymes (ALT, AST),3-Aged between 18 and 70 years,4-The first visit is to treat fatty liver disease.Exclusion criteria included were: 1.Alcoholism, 2 Have a history of diabetes, cardiovascular disease, various cancers, diseases of the liver (hepatitis, liver failure, cirrhosis), kidney failure and gastrointestinal bleeding wound, 3. Being pregnant and breastfeeding infant,4-Not wanting to continue the study,5- BMI> 35,6.Have any allergies to medications,7-The use of any supplement (including herbal supplements) and vitamins such as vitamin A, H, B (2,6,12 and complex), C, D).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Liver enzymes. Timepoint: 3 months after the intervention. Method of measurement: Using the Spectrophotometer IU/L.;LDL Cholesterol. Timepoint: Three months after the intervention. Method of measurement: using a spectrophotometer mg / dl.;HDL Cholesterol. Timepoint: Three months after the intervention. Method of measurement: using a spectrophotometer mg/dl.;Triglyceride. Timepoint: Three months after the intervention. Method of measurement: using a spectrophotometer mg / dl.;Fasting sugar. Timepoint: Three months after the intervention. Method of measurement: using a spectrophotometer mg / dl.;Body mass index. Timepoint: Three months after the intervention. Method of measurement: Kg/m2.

Secondary

MeasureTime frame
Blood presure. Timepoint: Introduction to the study and three months after the intervention. Method of measurement: Using the mercury pressure gauge.;The number of blood cells. Timepoint: Introduction to the study and three months after the intervention. Method of measurement: Using the auto blood cell counting analyzer.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmohammad bagher majnooni

Kermanshah University of Medical Sciences

bagher_1985@yahoo.comdr.ahmadi_jouybari@yahoo.comaghaei.a@sbmu.ac.ir+98 83 3835 8239

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026